

# ASSESSMENT OF ASTHMA CONTROL

## GINA 2025<sup>1</sup>



© 2025 Global Strategy Asthma Management and Prevention, all rights reserved. Use is by express license from the owner.

**It is important to assess a patient's risk factors for exacerbations which may be independent of symptom control**

**NAEPP and GINA both classify asthma control in terms of symptom impairment and future risk.<sup>1,2</sup>**

**GINA assessment of asthma control at clinical visits in adults, adolescents and children 6-11 years**

### A. Recent asthma symptom control (but also ask the patient/caregiver about the whole period since last review\*)

In the past 4 weeks, has the patient had:

- |   |  |
|---|--|
| • Daytime asthma symptoms more than twice/week?                 | Yes <input type="checkbox"/> No <input type="checkbox"/> |
| • Any night waking due to asthma?                               | Yes <input type="checkbox"/> No <input type="checkbox"/> |
| • SABA <sup>†</sup> reliever for symptoms more than twice/week? | Yes <input type="checkbox"/> No <input type="checkbox"/> |
| • Any activity limitation due to asthma?                        | Yes <input type="checkbox"/> No <input type="checkbox"/> |

Well controlled	Partly controlled	Uncontrolled
None of these	1–2 of these	3–4 of these

### B. Risk factors for poor asthma outcomes

Assess risk factors at diagnosis and periodically, including after an exacerbation.

Measure FEV<sub>1</sub> at start of treatment, after 3–6 months of ICS-containing treatment to record the patient's personal best lung function, then periodically for ongoing risk assessment.

#### i. Risk factors for exacerbations

**Uncontrolled asthma symptoms:** Having uncontrolled symptoms is an important risk factor for exacerbations.<sup>89</sup>

Factors that increase the risk of exacerbations even if the patient has few asthma symptoms<sup>‡</sup>:<sup>14,90,91</sup>

**SABA over-use:** High SABA use (≥3 x 200-dose canisters/year associated with increased risk of exacerbations, increased mortality particularly if ≥1 canister per month)<sup>92,95</sup>

**Inadequate ICS:** not prescribed ICS, poor adherence,<sup>96</sup> or incorrect inhaler technique<sup>97</sup>

**Other medical conditions:** Obesity,<sup>14,91,98,99</sup> chronic rhinosinusitis,<sup>14,99</sup> GERD,<sup>99</sup> confirmed food allergy,<sup>100</sup> pregnancy<sup>101</sup>

**Exposures:** Smoking,<sup>91,102</sup> e-cigarettes,<sup>103</sup> allergen exposure if sensitized,<sup>102,104</sup> air pollution<sup>105–108</sup>

**Psychosocial:** Major psychological or socioeconomic problems<sup>109,110</sup>

**Lung function:** Low FEV<sub>1</sub> (especially <60% predicted),<sup>102,111</sup> high bronchodilator responsiveness<sup>99,112,113</sup>

**Type 2 inflammatory markers:** Raised blood eosinophils,<sup>14,99,114,115</sup> high FeNO<sup>14,116</sup> (see biomarker overview, p.216)

**Exacerbation history:** Ever intubated or in intensive care unit for asthma,<sup>117</sup> ≥1 severe exacerbation in last year<sup>118,119</sup>

#### ii. Risk factors for developing persistent airflow limitation

**History:** Preterm birth, low birth weight and greater infant weight gain,<sup>120</sup> frequent productive cough<sup>121,122</sup>

**Medications:** Lack of ICS treatment in patient with history of severe exacerbation<sup>123</sup>

**Exposures:** Tobacco smoke,<sup>121</sup> noxious chemicals; occupational or domestic exposures<sup>95</sup>

**Investigation findings:** Low initial FEV<sub>1</sub>,<sup>122</sup> sputum or blood eosinophilia<sup>122</sup>

#### iii. Risk factors for medication side-effects

**Systemic** Frequent OCS, long-term, high-dose and/or potent ICS, cytochrome P450 inhibitors<sup>124</sup>

**Local:** High-dose or potent ICS,<sup>124,125</sup> poor inhaler technique<sup>126</sup>

FeNO: fractional exhaled nitric oxide; FEV<sub>1</sub>: forced expiratory volume in 1 second; GERD: gastro-esophageal reflux disease; ICS: inhaled corticosteroid; SABA: short-acting beta<sub>2</sub>-agonist; OCS: oral corticosteroid. \*In addition to assessing recent asthma symptom control, also ask the patient about symptom control over the whole period since their last clinical review. There are no validated tools for assessing long-term symptom control (>4 weeks); † Based on SABA (as-needed ICS-formoterol reliever not included); excludes reliever taken before exercise (see Assessing asthma symptom control, p.38); ‡ Independent risk factors after adjustment for the level of symptom control. Some studies have evaluated several of the above risk factors for exacerbations;<sup>14,90,91</sup> § Cytochrome P450 inhibitors such as ritonavir, ketoconazole, itraconazole may increase systemic exposure to some types of ICS and some long-acting beta<sub>2</sub>-agonists; see drug interaction websites and p.122 for details. For children 6–11 years, also refer to Box 2-3, p.40. See Box 3-5, p.56 for specific risk reduction strategies.

# ASSESSMENT OF ASTHMA CONTROL (cont'd)

## NAEPP 2007<sup>2</sup>

Level of control is determined by assessing both impairment and risk, and is based on the most severe category.

Assess impairment domain by patient's recall of previous 2–4 weeks and by spirometry/ or peak flow measures.

For treatment purposes, patients having had  $\geq 2$  prior-year exacerbations requiring oral steroids in the last year may be considered as having not well-controlled asthma, even if the patient has well-controlled symptoms.

COMPONENTS OF CONTROL		CLASSIFICATION OF ASTHMA CONTROL (≥12 years of age)		
		Well-Controlled	Not Well-Controlled	Very Poorly Controlled
Impairment	Symptoms	≤2 days/week	>2 days/week	Throughout the day
	Nighttime awakenings	≤2x/month	1-3x/week	≥4x/week
	Interference with normal activity	None	Some limitation	Extremely limited
	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week	Several times per day
	FEV <sub>1</sub> or peak flow	>80% predicted/personal best	60-80% predicted/personal best	<60% predicted/personal best
	Validated questionnaires ATAQ ACQ ACT	0 ≤0.75* ≥20	1-2 ≥1.5 16-19	3-4 N/A ≤15
Risk	Exacerbations requiring oral systemic corticosteroids	0-1/year	≥2/year (see note)	
		Consider severity and interval since last exacerbation		
	Progressive loss of lung function	Evaluation requires long-term follow-up care.		
	Treatment-related adverse effects	Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.		

\*ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma.

EIB, exercise-induced bronchospasm; FEV<sub>1</sub>, forced expiratory volume in 1 second.

Source: National Heart, Lung, and Blood Institute; National Institutes of Health; US Department of Health and Human Services.

**Note:** At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater disease severity.

The Asthma Impairment and Risk Questionnaire (AIRQ<sup>®</sup>) is the only control tool that assesses both symptom impairment and exacerbation risk in a single test.<sup>3</sup>

SCAN here to visit [airqscore.com](http://airqscore.com)



# TREATMENT APPROACHES FOR AGES ≥12 YEARS

## GINA 2025<sup>1</sup>

### Strategy for Asthma Management from GINA:

- SABA-only treatment of asthma is no longer recommended. The risk of severe exacerbations and mortality increases incrementally with higher SABA use, independent of treatment step
- While the assessment of symptom control includes a criterion for SABA reliever use on ≤2 versus >2 days/week, it does not include a similar criterion for an anti-inflammatory reliever. Assess the average frequency of reliever use over the past 4 weeks when the ICS maintenance dose is reviewed.

### Treatment steps in adults and adolescents with a diagnosis of asthma



#### NOTE:

The use of ICS-formoterol is not approved for maintenance plus rescue therapy or for as-needed rescue only in the US. The recommendations for ICS-formoterol are based on clinical data evaluating the use of ICS-formoterol formulations and strengths not approved and not available in the US.

### GINA 2025 – Adults & adolescents 12+ years

#### Personalized asthma management

Assess, Adjust, Review for individual patient needs

Symptoms  
Exacerbations  
Side-effects  
Comorbidities  
Lung function  
Consider biomarkers  
Patient (and parent/caregiver) satisfaction



Confirmation of diagnosis if necessary  
Symptom control & modifiable risk factors  
Comorbidities  
Inhaler technique & adherence  
Patient (and parent/caregiver) preferences and goals

Treatment of modifiable risk factors and comorbidities  
Non-pharmacological strategies  
Asthma medications including ICS  
Education & skills training, action plan

**TRACK 1: PREFERRED**  
**CONTROLLER and RELIEVER**  
Using ICS-formoterol as the reliever\* reduces the risk of exacerbations compared with using a SABA reliever, and is a simpler regimen

#### STEPS 1 – 2

AIR-only\*: low-dose ICS-formoterol as needed

**STEP 3**  
MART\* with low-dose maintenance ICS-formoterol

**STEP 4**  
MART\* with medium-dose maintenance ICS-formoterol

**STEP 5**  
Add-on LAMA  
Refer for assessment of phenotype. Consider trial of high-dose maintenance ICS-formoterol. Consider anti-IgE, anti-IL5/5R, anti-IL4Rα, anti-TSLP

RELIEVER: As-needed low-dose ICS-formoterol\*

**TRACK 2: Alternative**  
**CONTROLLER and RELIEVER**  
Before considering a regimen with SABA reliever, check if the patient is likely to adhere to daily controller treatment

**STEP 1**  
Reliever only; if SABA, take ICS with each dose

**STEP 2**  
Low dose maintenance ICS

**STEP 3**  
Low dose maintenance ICS-LABA

**STEP 4**  
Medium dose maintenance ICS-LABA

**STEP 5**  
Add-on LAMA  
Refer for assessment of phenotype. Consider trial of high-dose maintenance ICS-LABA. Consider anti-IgE, anti-IL5/5R, anti-IL4Rα, anti-TSLP

RELIEVER: as-needed ICS-SABA\*, or as-needed SABA

Non-pharmacologic strategies include smoking cessation, physical activity, pulmonary rehabilitation, weight reduction, vaccinations (see text for more)  
Allergen immunotherapy, e.g. HDM SLIT: consider for patients with clinically relevant sensitization and not well-controlled (but stable) asthma. See text for further information and safety advice  
Additional controller options (e.g., add-on LAMA at Step 4, add-on LTRA) have less evidence for efficacy or for safety than Tracks 1 or 2 (see text). Maintenance OCS should only ever be used as last resort.

\*AIR: Anti-inflammatory reliever; Ig: immunoglobulin; ICS: inhaled corticosteroids; HDM: house dust mites; IL: interleukin; LABA: long-acting beta<sub>2</sub>-agonist; LAMA: long-acting muscarinic antagonist; MART: maintenance-and reliever therapy with ICS-formoterol; OCS: oral corticosteroid; SLIT: sublingual immunotherapy; TSLP: thymic stromal lymphopoietin. †If prescribing LTRA, advise patient/caregiver about risk of neuropsychiatric adverse effects.  
For recommendations about initial asthma treatment in adults and adolescents, see Box 4-4 (p.75) and Box 4-5 (p.76). See Box 4-2 (p.71) for low, medium and high ICS doses for adults and adolescents. See Box 4-8 (p.84) for Track 1 medications and doses.

© 2025 Global Strategy Asthma Management and Prevention, all rights reserved. Use is by express license from the owner.

ICS-formoterol should not be used as the reliever for patients taking a different maintenance ICS-LABA. The use of ICS-formoterol with other LABAs may be associated with increased adverse effects.<sup>1</sup>

# TREATMENT APPROACHES FOR AGES ≥12 YEARS (cont'd)

## NAEPP Focused Update 2020<sup>4</sup>

- Supports the use of concomitant ICS with a fast-acting bronchodilator as part of rescue therapy
- Concomitant SABA and ICS is one of the preferred options at step 2 treatment
- Single maintenance and reliever therapy (SMART) is suggested for step 3 and 4 treatment
- Individuals whose asthma is uncontrolled on maintenance ICS-LABA with SABA as quick relief therapy, should receive the preferred SMART if possible before moving to a higher step in therapy

### AGES 12+ YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

Treatment	Management of Persistent Asthma in Individuals Ages 12+ Years					
	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6
<b>Preferred</b>	PRN SABA	Daily low-dose ICS and PRN SABA or PRN concomitant ICS and SABA <sup>▲</sup>	Daily and PRN combination low-dose ICS-formoterol <sup>▲</sup>	Daily and PRN combination medium-dose ICS-formoterol <sup>▲</sup>	Daily medium-high dose ICS-LABA + LAMA and PRN SABA <sup>▲</sup>	Daily high-dose ICS-LABA + oral systemic corticosteroids + PRN SABA
<b>Alternative</b>		Daily LTRA* and PRN SABA or Cromolyn,* or Nedocromil,* or Zileuton,* or Theophylline,* and PRN SABA	Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LAMA, <sup>▲</sup> or daily low-dose ICS + LTRA,* and PRN SABA or Daily low-dose ICS + Theophylline* or Zileuton,* and PRN SABA	Daily medium-dose ICS-LABA or daily medium-dose ICS + LAMA, and PRN SABA <sup>▲</sup> or Daily medium-dose ICS + LTRA,* or daily medium-dose ICS + Theophylline,* or daily medium-dose ICS + Zileuton,* and PRN SABA	Daily medium-high dose ICS-LABA or daily high-dose ICS + LTRA,* and PRN SABA	
					Consider adding Asthma Biologics (eg, anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13). <sup>**</sup>	

<sup>▲</sup>Updated based on the 2020 guidelines. \*Cromolyn, Nedocromil, LTRAs including Zileuton and montelukast, and Theophylline were not considered for this update, and/or have limited availability for use in the United States, and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable. The FDA issued a Boxed Warning for montelukast in March 2020. <sup>\*\*</sup>The AHRQ systematic reviews that informed this report did not include studies that examined the role of asthma biologics (eg, anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13). Thus, this report does not contain specific recommendations for the use of biologics in asthma in Steps 5 and 6.



**NOTE:** The use of ICS-formoterol is not approved for maintenance plus rescue therapy or for as-needed rescue only in the US. The recommendations for ICS-formoterol are based on clinical data evaluating the use of ICS-formoterol formulations and strengths not approved and not available in the US.

The NAEPP 2020 Focused Updates did not include new research or the US FDA approval of multiple drugs classified as asthma biologics occurring after October 2018.

The tables and figures are selections from the National Asthma Education and Prevention Program's (NAEPP) Expert Panel Report EPR-3 (2007) and 2020 Focused Updates to the Asthma Management Guidelines, and the Global Initiative for Asthma (GINA) 2025 Report. Please refer to the complete reports for additional information and full context.

This is not a comprehensive compilation of all content from these sources. The intent of this document is to provide a quick summary tool.

ACQ<sup>®</sup>, Asthma Control Questionnaire<sup>®</sup>; ACT<sup>™</sup>, Asthma Control Test<sup>™</sup>; AHRQ, Agency for Healthcare Research and Quality; ATAQ<sup>®</sup>, Asthma Therapy Assessment Questionnaire<sup>®</sup>; EIB, exercise-induced bronchospasm; FDA, Food and Drug Administration; FeNO, fractional exhaled nitric oxide; FEV<sub>1</sub>, forced expiratory volume in one second; GERD, gastroesophageal reflux disease; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IgE, immunoglobulin E; IL4Rα, interleukin 4 receptor α; IL5, interleukin 5; IL5R, interleukin 5 receptor; IL13, interleukin 13; LABA, long-acting beta<sub>2</sub>-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; MART, maintenance and rescue therapy; NAEPP, National Asthma Education and Prevention Program; OCS, oral corticosteroids; PRN, as-needed; SABA, short-acting beta<sub>2</sub>-agonist; SCS, systemic corticosteroids; TSLP, thymic stromal lymphopoietin.

1. Global Initiative for Asthma, 2025. Available at: [www.ginasthma.org](https://www.ginasthma.org). Accessed June 25, 2025. 2. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma, 2007. Available at: [https://www.ncbi.nlm.nih.gov/books/NBK7232/pdf/Bookshelf\\_NBK7232.pdf](https://www.ncbi.nlm.nih.gov/books/NBK7232/pdf/Bookshelf_NBK7232.pdf). Accessed June 25, 2025. 3. Murphy KR, Chipps B, Beuther DA, et al. Development of the asthma impairment and risk questionnaire (AIRQ): a composite control measure. *J Allergy Clin Immunol Pract*. 2020;8(7):2263-2274.e5. 4. NAEPPCC Expert Panel Working Group. 2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol*. 2020;146:1217-1270.